Open AccessMolecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma
Author(s) -
Fabien Robin,
Gaëlle Angenard,
Luis Cano,
Laëtitia Courtin-Tanguy,
Elodie Gaignard,
Z. Khene,
Damien Bergeat,
Bruno Clément,
Karim Boudjéma,
Cédric Coulouarn,
Laurent Sulpice
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0863-1
Subject(s) - stroma , stromal cell , immunohistochemistry , pancreatic cancer , tissue microarray , pathology , metastasis , tgfbi , gene expression profiling , biomarker , cancer research , adenocarcinoma , cancer , microdissection , biology , laser capture microdissection , medicine , gene expression , gene , transforming growth factor , biochemistry
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer worldwide, as a result of a late diagnosis and limited therapeutic options. Tumour microenvironment (or stroma) plays a key role in cancer onset and progression and constitutes an intrinsic histological hallmark of PDAC. Thus we hypothesised that relevant prognostic biomarkers and therapeutic targets can be identified in the stroma.